Industry
Biotechnology
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Loading...
Open
1.55
Mkt cap
76M
Volume
915K
High
1.63
P/E Ratio
-0.40
52-wk high
17.82
Low
1.44
Div yield
N/A
52-wk low
1.33
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 2:22 pm
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 2:15 pm
Portfolio Pulse from Vandana Singh
August 01, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 1:01 pm
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 12:32 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 11:49 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 8:25 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 8:03 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 8:00 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 7:44 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.